These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 7044593)

  • 1. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.
    Issell BF; Tihon C; Curry ME
    Cancer Chemother Pharmacol; 1982; 7(2-3):113-5. PubMed ID: 7083450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current development of podophyllotoxins.
    Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
    Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podophyllotoxin derivatives.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1991; 12():75-81. PubMed ID: 1931460
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships among glycosidic derivatives of 4'-demethylepipodophyllotoxin and epipodophyllotoxin, showing VM26- and VP16-213-like activities.
    Gupta RS; Chenchaiah PC; Gupta R
    Anticancer Drug Des; 1987 Aug; 2(1):1-12. PubMed ID: 3449081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects.
    Dombernowsky P; Hansen HH
    Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960
    [No Abstract]   [Full Text] [Related]  

  • 8. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
    Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR
    Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay.
    Matsushima Y; Kanzawa F; Miyazawa N; Sasaki Y; Saijo N
    Anticancer Res; 1986; 6(5):921-4. PubMed ID: 3026235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26.
    Minocha A; Long BH
    Biochem Biophys Res Commun; 1984 Jul; 122(1):165-70. PubMed ID: 6331440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
    Allen LM; Tejada F; Okonmah AD; Nordqvist S
    Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 16. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 17. VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.
    Loike JD
    Cancer Chemother Pharmacol; 1982; 7(2-3):103-11. PubMed ID: 7044591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
    Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
    Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
    Long BH; Musial ST; Brattain MG
    Biochemistry; 1984 Mar; 23(6):1183-8. PubMed ID: 6712942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.